Literature DB >> 15985227

Comparative evaluation of intranasal and subcutaneous route of immunization for development of mucosal vaccine against experimental tuberculosis.

Pramod K Giri1, Suraj B Sable, Indu Verma, Gopal K Khuller.   

Abstract

Activation of mucosal immunity in the respiratory tract is crucial for protection against respiratory infections. Whether the intranasal route of vaccination imparts better protection against pulmonary tuberculosis than that of subcutaneous vaccination remains a debatable issue. In this study, we have investigated the effect of the routes of immunization on the induction of immunoprotection against experimental tuberculosis employing mycobacterial culture filtrate proteins complexed with dimethyldioctadecylammonium bromide. Vaccination via intranasal and subcutaneous routes triggered immune activation in the spleen and cervical lymph node, while the former route of vaccination lead to higher antigen-specific lymphocyte proliferation, interferon-gamma, interleukin-12 and interleukin-4 responses in cervical lymph node and induction of antigen-specific IgA responses at mucosal level of the respiratory tract. Mice vaccinated via the intranasal route were found to be better protected against experimental tuberculosis particularly in lung compared to subcutaneous-immunized mice. These results emphasize the importance of the intranasal route vaccination in tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15985227     DOI: 10.1016/j.femsim.2005.02.009

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  19 in total

1.  Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responses.

Authors:  Juliana Bessa; Franziska Zabel; Alexander Link; Andrea Jegerlehner; Heather J Hinton; Nicole Schmitz; Monika Bauer; Thomas M Kündig; Philippe Saudan; Martin F Bachmann
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-20       Impact factor: 11.205

2.  Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis.

Authors:  Anna Easton; Ashraful Haque; Karen Chu; Natasha Patel; Roman A Lukaszewski; Arthur M Krieg; Richard W Titball; Gregory J Bancroft
Journal:  J Infect Dis       Date:  2011-08-15       Impact factor: 5.226

3.  The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.

Authors:  Claire Swetman Andersen; Jes Dietrich; Else Marie Agger; Nils Y Lycke; Karin Lövgren; Peter Andersen
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

4.  Influence of maternal gestational treatment with mycobacterial antigens on postnatal immunity in an experimental murine model.

Authors:  Muhammad Jubayer Rahman; Irene Roman Dégano; Mahavir Singh; Carmen Fernández
Journal:  PLoS One       Date:  2010-03-15       Impact factor: 3.240

5.  Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis.

Authors:  Jingyu Mu; Mangalakumari Jeyanathan; Cherrie-Lee Small; Xizhong Zhang; Elizabeth Roediger; Xueya Feng; Duncan Chong; Jack Gauldie; Zhou Xing
Journal:  Mol Ther       Date:  2009-03-24       Impact factor: 11.454

6.  Primary activation of antigen-specific naive CD4+ and CD8+ T cells following intranasal vaccination with recombinant bacteria.

Authors:  Annalisa Ciabattini; Elena Pettini; Peter Andersen; Gianni Pozzi; Donata Medaglini
Journal:  Infect Immun       Date:  2008-10-06       Impact factor: 3.441

7.  A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus.

Authors:  Byron E E Martina; Petra van den Doel; Penelope Koraka; Geert van Amerongen; Gunther Spohn; Bart L Haagmans; Lisette B V Provacia; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

Review 8.  Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID).

Authors:  Amir Seyfoori; Mahdieh Shokrollahi Barough; Pooneh Mokarram; Mazaher Ahmadi; Parvaneh Mehrbod; Alireza Sheidary; Tayyebeh Madrakian; Mohammad Kiumarsi; Tavia Walsh; Kielan D McAlinden; Chandra C Ghosh; Pawan Sharma; Amir A Zeki; Saeid Ghavami; Mohsen Akbari
Journal:  Int J Mol Sci       Date:  2021-06-28       Impact factor: 5.923

9.  Intranasal immunization of baculovirus displayed hemagglutinin confers complete protection against mouse adapted highly pathogenic H7N7 reassortant influenza virus.

Authors:  Subaschandrabose Rajesh Kumar; Syed Musthaq Syed Khader; Tanja K Kiener; Milene Szyporta; Jimmy Kwang
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

10.  Roles of Mucosal Immunity against Mycobacterium tuberculosis Infection.

Authors:  Wu Li; Guangcun Deng; Min Li; Xiaoming Liu; Yujiong Wang
Journal:  Tuberc Res Treat       Date:  2012-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.